RIP1 Kinase Inhibitors for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases associated with receptor-interacting protein-1 kinase (RIP1) are inadequate, as existing therapies fail to effectively inhibit RIP1 activity, leading to persistent inflammation and tissue damage.
Innovation Solution
Development of novel compounds with a specific chemical formula that selectively inhibit RIP1 kinase activity, thereby reducing inflammation and treating associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat inflammatory diseases, then treatment is provided, but RIP1 activity is not effectively inhibited, leading to persistent inflammation and tissue damage
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of RIP1 inhibitors through systematic variation of molecular components. The invention explores different substituents (R1-R6 groups), linkage types (L), and molecular configurations to optimize binding affinity and inhibitory potency. This structural parameter optimization enables effective RIP1 inhibition while minimizing harmful effects, directly resolving the contradiction between reliable inhibition and reduction of harmful factors.
Solution Approach 2:
The patent employs composite material principles by integrating multiple functional moieties into a single inhibitor molecule. The compounds combine various pharmacophores and structural elements (including heteroaryl rings, alkyl chains, and functional groups) to create a synergistic inhibitor that effectively targets RIP1. This composite approach enhances inhibitory effectiveness while reducing side effects, addressing the technical contradiction.
2Reliability
If novel compounds with specific chemical formulas are developed, then RIP1 kinase activity is selectively inhibited, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the complex inhibitor molecule into distinct functional segments or modules. Each segment (such as specific substituents R1-R6, linkage types L, and core structures) can be independently designed, synthesized, and optimized. This modular segmentation simplifies the overall synthesis process and enables parallel development of different compound series, reducing the complexity burden while maintaining selective RIP1 inhibition.
Solution Approach 2:
The patent employs universality by designing a core molecular framework that can accommodate multiple substituents and configurations. This universal scaffold allows a single base structure to generate multiple inhibitor variants through systematic substitution, reducing the need to synthesize entirely new compounds from scratch. The multi-functional design enables selective RIP1 inhibition across different disease models while streamlining synthesis and characterization efforts.
Data Source
AI summary
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.